User login
Key clinical point: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was associated with 25% improved clinical remission rates compared with tumor necrosis factor inhibitors (TNFi) monotherapy in patients with psoriatic arthritis (PsA) who initiated first-ever TNFi.
Major finding: At 12 months, the rate of achieving clinical remission was significantly higher with comedication vs. monotherapy (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.12-1.41). Methotrexate comedication showed better remission for adalimumab (OR, 1.45; 95% CI, 1.23-1.72) and infliximab (OR, 1.55; 95% CI, 1.21-1.98) vs. monotherapy. No effect of comedication was observed for etanercept.
Study details: The data come from an observational study of 15,332 patients with PsA who initiated treatment with TNFi, of whom 9,440 were included in the TNFi and csDMARD comedication group and 5,892 in the TNFi monotherapy group.
Disclosures: This work was supported by Novartis. The authors including the lead author reported receiving consulting fees, speaking fees, and/or honoraria from various sources.
Source: Lindström U et al. Ann Rheum Dis. 2021 Jun 3. doi: 10.1136/annrheumdis-2021-220097.
Key clinical point: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was associated with 25% improved clinical remission rates compared with tumor necrosis factor inhibitors (TNFi) monotherapy in patients with psoriatic arthritis (PsA) who initiated first-ever TNFi.
Major finding: At 12 months, the rate of achieving clinical remission was significantly higher with comedication vs. monotherapy (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.12-1.41). Methotrexate comedication showed better remission for adalimumab (OR, 1.45; 95% CI, 1.23-1.72) and infliximab (OR, 1.55; 95% CI, 1.21-1.98) vs. monotherapy. No effect of comedication was observed for etanercept.
Study details: The data come from an observational study of 15,332 patients with PsA who initiated treatment with TNFi, of whom 9,440 were included in the TNFi and csDMARD comedication group and 5,892 in the TNFi monotherapy group.
Disclosures: This work was supported by Novartis. The authors including the lead author reported receiving consulting fees, speaking fees, and/or honoraria from various sources.
Source: Lindström U et al. Ann Rheum Dis. 2021 Jun 3. doi: 10.1136/annrheumdis-2021-220097.
Key clinical point: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was associated with 25% improved clinical remission rates compared with tumor necrosis factor inhibitors (TNFi) monotherapy in patients with psoriatic arthritis (PsA) who initiated first-ever TNFi.
Major finding: At 12 months, the rate of achieving clinical remission was significantly higher with comedication vs. monotherapy (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.12-1.41). Methotrexate comedication showed better remission for adalimumab (OR, 1.45; 95% CI, 1.23-1.72) and infliximab (OR, 1.55; 95% CI, 1.21-1.98) vs. monotherapy. No effect of comedication was observed for etanercept.
Study details: The data come from an observational study of 15,332 patients with PsA who initiated treatment with TNFi, of whom 9,440 were included in the TNFi and csDMARD comedication group and 5,892 in the TNFi monotherapy group.
Disclosures: This work was supported by Novartis. The authors including the lead author reported receiving consulting fees, speaking fees, and/or honoraria from various sources.
Source: Lindström U et al. Ann Rheum Dis. 2021 Jun 3. doi: 10.1136/annrheumdis-2021-220097.